Skip to main content

Table 1 Detail of included studies

From: Liberal versus restrictive red blood cell transfusion strategy in sepsis or septic shock: a systematic review and meta-analysis of randomized trials

 TRICOPTRISSTRICC
First author, yearBergamin, 2017 [14]Holst, 2014 [8]Hebert, 1999 [15]
CountryBrazilDenmark, Sweden, Norway FinlandCanada
No of site13225
Inclusion period2012–20142011–20131994–1997
No of patients300998218 (subgroup)
Type of patientsCancer patients with septic shock ( 18 years old)Patients with septic shock ( 18 years old)Patients with severe infection or septic shock ( 16 years old)
Source of infection [liberal (%) vs restrictive (%)]
 Lungs69 vs 6152.2 vs 53.2 
 Abdomen13 vs 1739.9 vs 41.0Unknown
 Urinary tract9 vs 512.3 vs 11.6 
 Other9 vs 1721.4 vs 21.8 
Exclusion criteria (yes: excluded, no: not excluded)
 Life-threating/uncontrolled bleedingYesYesYes
 Acute myocardial ischemiaNoYesNo
 Admission after cardiac surgeryNoNoYes
 Hematologic cancerYesNoNo
 Acute burn injuryNoYesNo
 End-stage renal diseaseYesNoNo
 PregnancyNoNoYes
 Anticoagulation therapyYesNoNo
 Withdrawal from active therapyYesYesYes
 Hemoglobin threshold [liberal (g/dL) vs restrictive (g/dL)]< 9 vs < 7< 9 vs < 7< 10 vs < 7
 Severity of patients (SOFA score) [median (interquartile range)]Liberal; 6 (5–9)Liberal; 10 (8–12)Unknown
Restrictive; 7 (5–9)Restrictive; 10 (8–12)
 Timing of randomization after ICU admission (h) [median (interquartile range)]Within 6 hLiberal; 20 (7–43)Within 72 h
Restrictive; 23 (7–50)
 Intervention periodICU stayICU stayICU stay
 LeukodepletionYesYesNo
 OutcomesMortality (28, 60, 90 days)Mortality (28, 60, 90 days)Mortality (30 days)
Ischemic eventsIschemic events
Severe adverse reactionsSevere adverse reactions
Use of life support at 28 daysUse of life support at 28 days
Number of patients transfused in the ICUNumber of patients transfused in the ICU